Key Takeaways
- • Archimed has invested in Organika, a Vancouver-headquartered nutraceutical company founded in 1990, marking the first deal from its MED IV fund.
- • Organika manufactures supplements across hydration, collagen, protein, immunity, gut health and sleep categories.
- • The transaction positions MED IV's first investment in the healthcare consumer nutrition segment, according to PE Hub.
- • Limited deal terms, including valuation and stake size, were not disclosed in the available source material.
Summary
French private equity firm Archimed has made an investment in Organika, a Vancouver-headquartered nutraceutical company, according to PE Hub. The transaction is the first deal completed by MED IV, Archimed's fund in the healthcare sector.
Founded in 1990, Organika develops and markets a range of dietary supplements spanning hydration, collagen, protein, immunity, gut health and sleep. The company's product breadth positions it within the consumer health and wellness segment, an area that has attracted sustained private equity interest in recent years.
The available reporting does not disclose the financial terms of the transaction, including the purchase price, the size of Archimed's stake, or the identity of any selling shareholders. Details on the company's revenue, growth trajectory or the strategic rationale articulated by Archimed were also not included in the source material.
For institutional investors tracking MED IV, the deal serves as the initial data point on the fund's investment strategy and sector focus. Further details on deal economics and portfolio construction would be needed to assess the transaction's significance relative to the fund's target returns.
Founded in 1990, Organika develops and markets a range of dietary supplements spanning hydration, collagen, protein, immunity, gut health and sleep. The company's product breadth positions it within the consumer health and wellness segment, an area that has attracted sustained private equity interest in recent years.
The available reporting does not disclose the financial terms of the transaction, including the purchase price, the size of Archimed's stake, or the identity of any selling shareholders. Details on the company's revenue, growth trajectory or the strategic rationale articulated by Archimed were also not included in the source material.
For institutional investors tracking MED IV, the deal serves as the initial data point on the fund's investment strategy and sector focus. Further details on deal economics and portfolio construction would be needed to assess the transaction's significance relative to the fund's target returns.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.